James A Chiarotto1, George Dranitsaris. 1. Department of Medicine, Oncology Program, Rouge Valley Health System, 2863 Ellesmere Road, Toronto, Ontario, M1E 5E9, Canada, jchiarotto@bell.net.
Abstract
PURPOSE: Does giving full-dose adjuvant chemotherapy to patients with early stage breast cancer (ESBC) regardless of the day-before absolute neutrophil count (ANC) lead to an increased incidence of chemotherapy-induced febrile neutropenia (CIFN)? What factors may predispose patients to CIFN? METHODS: This was a retrospective chart review conducted on all patients receiving adjuvant chemotherapy for ESBC at a mid-sized community hospital in Toronto, Ontario, Canada between September 2005 and August 2011. Day-before CBC data were collected along with other patient characteristics. CIFN was confirmed by hospital records. One hundred fifty-four patients met the inclusion criteria. Overall, 830 cycles of chemotherapy were analyzed. Univariate and multivariate logistic regression analyses were used to identify risk factors for CIFN. RESULTS: Twenty-two episodes of CIFN were observed. There was no significant difference in day-before ANC between patients who developed CIFN relative to those who did not. The day-before ANC was <1.5 × 10(9)/L for 88 cycles of chemotherapy. ANC analyzed as a continuous variable showed that the odds ratio (OR) for CIFN was 0.97 (95 % CI 0.82-1.13, p = NS). The pseudo R (2) statistic, which is a measure of variability accounted for by a regression model, was only 0.0008, indicating that ANC explained less than 1 % of the variability in the risk of CIFN. The most significant predictor of CIFN was the chemotherapy regimen, with docetaxel (Taxotere)/cyclophosphamide demonstrating the highest risk (OR 7.1, 95 % CI 1.4-34.9, p = 0.016). CONCLUSIONS: Full-dose adjuvant chemotherapy may be given to patients with ESBC regardless of the day-before ANC, without significantly increasing the risk of CIFN. The chemotherapy regimen is the most significant predictor for CIFN.
PURPOSE: Does giving full-dose adjuvant chemotherapy to patients with early stage breast cancer (ESBC) regardless of the day-before absolute neutrophil count (ANC) lead to an increased incidence of chemotherapy-induced febrile neutropenia (CIFN)? What factors may predispose patients to CIFN? METHODS: This was a retrospective chart review conducted on all patients receiving adjuvant chemotherapy for ESBC at a mid-sized community hospital in Toronto, Ontario, Canada between September 2005 and August 2011. Day-before CBC data were collected along with other patient characteristics. CIFN was confirmed by hospital records. One hundred fifty-four patients met the inclusion criteria. Overall, 830 cycles of chemotherapy were analyzed. Univariate and multivariate logistic regression analyses were used to identify risk factors for CIFN. RESULTS: Twenty-two episodes of CIFN were observed. There was no significant difference in day-before ANC between patients who developed CIFN relative to those who did not. The day-before ANC was <1.5 × 10(9)/L for 88 cycles of chemotherapy. ANC analyzed as a continuous variable showed that the odds ratio (OR) for CIFN was 0.97 (95 % CI 0.82-1.13, p = NS). The pseudo R (2) statistic, which is a measure of variability accounted for by a regression model, was only 0.0008, indicating that ANC explained less than 1 % of the variability in the risk of CIFN. The most significant predictor of CIFN was the chemotherapy regimen, with docetaxel (Taxotere)/cyclophosphamide demonstrating the highest risk (OR 7.1, 95 % CI 1.4-34.9, p = 0.016). CONCLUSIONS: Full-dose adjuvant chemotherapy may be given to patients with ESBC regardless of the day-before ANC, without significantly increasing the risk of CIFN. The chemotherapy regimen is the most significant predictor for CIFN.
Authors: Jacques Bonneterre; Henri Roché; Pierre Kerbrat; Alain Brémond; Pierre Fumoleau; Moïse Namer; Marie-Josèphe Goudier; Simon Schraub; Pierre Fargeot; Isabelle Chapelle-Marcillac Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079
Authors: Gary H Lyman; Nicole M Kuderer; Jeffrey Crawford; Debra A Wolff; Eva Culakova; Marek S Poniewierski; David C Dale Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Matthias Schwenkglenks; Ruth Pettengell; Christian Jackisch; Robert Paridaens; Manuel Constenla; André Bosly; Thomas D Szucs; Robert Leonard Journal: Support Care Cancer Date: 2010-03-20 Impact factor: 3.603
Authors: Ruth Pettengell; Matthias Schwenkglenks; Robert Leonard; André Bosly; Robert Paridaens; Manuel Constenla; Thomas D Szucs; Christian Jackisch Journal: Support Care Cancer Date: 2008-03-20 Impact factor: 3.603
Authors: I Ray-Coquard; C Borg; Th Bachelot; C Sebban; I Philip; G Clapisson; A Le Cesne; P Biron; F Chauvin; J Y Blay Journal: Br J Cancer Date: 2003-01-27 Impact factor: 7.640